Market Voices: Lutnick on tariff deadlines, Boeing, Novo Nordisk

Seeking Alpha’s roundup of statements, announcements and remarks that could impact markets, sectors or individual stocks.

• Commerce Secretary Howard Lutnick said the Trump administration is set to impose “reciprocal” tariffs on Friday on countries that didn’t reach a trade deal with the U.S. by the Aug. 1 deadline.

“August 1 is the date that we’re setting all these rates, and they are off to the races after that,” Lutnick said during an interview with CNBC on Tuesday.

“What’s happened is many, many countries had made us okay offers to open their markets. You know, 50%, 30%,” Lutnick said. “The president said, ‘No, no, I want them open.’”

“So now the price of a deal with the United States of America is black and white, completely open markets,” Lutnick continued. “He wants to make sure that Americans can sell their goods overseas.”

“So are there deals on the table for him to consider? Yes,” Lutnick told CNBC, adding that Trump “knows that he can just set the rate and set the price and move on.”

• Lutnick also said that negotiations for a trade deal with China were proceeding on a separate timeline.

“We have our own team working with China. They’re their own thing,” Lutnick told CNBC. “But for the rest of the world, we’re going to have things done by Friday.”

U.S. and Chinese negotiators are currently meeting in Sweden to work out a potential deal.

• Boeing (NYSE:BA) CEO Kelly Ortberg said he believes 2025 is shaping up to be the aerospace company’s “turnaround year.”

“Change takes time, but we’re starting to see a difference in our performance across the business,” Ortberg said in a staff memo, according to CNBC.

“If we continue to tackle the important work ahead of us and focus on safety, quality and stability, we can navigate the dynamic global environment and make 2025 our turnaround year,” Ortberg added.

Boeing (NYSE:BA) reported better-than-expected Q2 earnings early Tuesday.

• Novo Nordisk (NVO) named company veteran Maziar Mike Doustdar as its new CEO after lowering its 2025 financial outlook due in part to slowed sales of its popular GLP-1 drugs Wegovy and Ozempic.

“I come to this role with a sense of urgency, a laser focus on high performance, and a fierce determination for Novo Nordisk to aim higher than it’s ever done, and to deliver to many more patients the innovation they need,” Doustdar said in a company statement announcing his appointment.

“This is an important moment for Novo Nordisk. The market is developing rapidly, and the company needs to address recent market challenges with speed and ambition,” said Novo Nordisk Chair Helge Lund in the same statement.

“I believe Novo Nordisk will build on its strengths as a global leader in obesity and diabetes, and Mike has a clear vision of how to unlock the full potential of the opportunities ahead,” Lund added.